| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/13/2000 | WO1999059617A3 Immunoregulator |
| 01/13/2000 | WO1999058118A3 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
| 01/13/2000 | WO1999055312A3 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 01/13/2000 | WO1999053953A3 Methods and products related to metabolic interactions in disease |
| 01/13/2000 | WO1999053060A3 Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| 01/13/2000 | WO1999038501A3 Method of regulating glucose metabolism, and reagents related thereto |
| 01/13/2000 | WO1999018941A3 Ih-MODULATORS |
| 01/13/2000 | DE19830732A1 Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff A composition comprising at least one lipid levels influencing drug |
| 01/13/2000 | DE19830201A1 Mittel mit antidepressiver Wirkung Agent with an antidepressant activity |
| 01/13/2000 | CA2379524A1 Salts and bases of the 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opiod analgesics |
| 01/13/2000 | CA2336739A1 Trifunctional reagent for conjugation to a biomolecule |
| 01/13/2000 | CA2336709A1 Use of inhibitors of protein kinase c epsilon to treat pain |
| 01/13/2000 | CA2336134A1 Use of texaphyrins in macrophage-mediated disease |
| 01/13/2000 | CA2333307A1 Compositions and methods for in vitro fertilization |
| 01/13/2000 | CA2331829A1 Kv6.2, a voltage-gated potassium channel subunit |
| 01/13/2000 | CA2331394A1 Human emr1-like g protein coupled receptor |
| 01/12/2000 | EP0970696A1 Combination of loop diuretics with adenosine A1-receptor antagonists |
| 01/12/2000 | EP0970695A1 Methods for increasing levels of acetylcholine |
| 01/12/2000 | EP0970379A1 Methods to identify beta-amyloid reducing agents |
| 01/12/2000 | EP0970372A1 Assay for disease related conformation of a protein |
| 01/12/2000 | EP0970227A1 Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
| 01/12/2000 | EP0970223A1 Serine/threonine protein kinase |
| 01/12/2000 | EP0970203A2 Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans |
| 01/12/2000 | EP0970198A2 Novel compounds |
| 01/12/2000 | EP0970186A1 SpoOJ2 OF STAPHYLOCOCCUS AUREUS |
| 01/12/2000 | EP0970122A1 Human anion channel |
| 01/12/2000 | EP0970120A2 Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions |
| 01/12/2000 | EP0970062A2 Pyrrolidine and thiazole derivatives with metallo-beta-lactamase inhibitory properties |
| 01/12/2000 | EP0969877A1 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 01/12/2000 | EP0969869A2 Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders |
| 01/12/2000 | EP0969868A2 Methods and kits for treating and diagnosing leiomyomas |
| 01/12/2000 | EP0969858A1 RIBOSOME RECYCLING FACTOR (FRR) OF $i(STAPHYLOCOCCUS AUREUS) |
| 01/12/2000 | EP0969855A1 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 01/12/2000 | EP0969852A1 Combination therapy for the treatment of diabetes and obesity |
| 01/12/2000 | EP0969851A1 Immunomodulatory complex and use thereof in helicobacter diseases |
| 01/12/2000 | EP0969847A1 Tazarotene and corticosteroid treatment for psoriasis |
| 01/12/2000 | EP0969845A1 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
| 01/12/2000 | EP0969844A1 Administration of an injectable antibiotic in the ear of an animal |
| 01/12/2000 | EP0969842A1 Pharmaceutical composition |
| 01/12/2000 | EP0969835A1 Use of central cannabinoid receptor antagonists for regulating appetence |
| 01/12/2000 | EP0969824A1 Use of inhibitors of undecaprenol kinase to inhibit cell wall biosynthesis |
| 01/12/2000 | EP0969823A2 Anti-epileptogenic agents |
| 01/12/2000 | EP0969821A1 Pellets having a core coated with an antifungal and a polymer |
| 01/12/2000 | EP0969817A1 Dosage forms having improved release properties |
| 01/12/2000 | EP0969813A2 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| 01/12/2000 | EP0969790A2 Compositions for treating acne rosacea |
| 01/12/2000 | EP0969720A2 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| 01/12/2000 | CN1240646A Injectable composition of non-steroidal anti-inflammatory drugs |
| 01/11/2000 | US6013672 Administering to an individual suffering from head, spinal cord trauma, stroke and epilepsy a therapeutically effective dose of a metabotropic glutamate receptor agonist |
| 01/11/2000 | US6013665 Administering to a animal a triglyceride containg atleast 33 to 70 weight% medium acyl chain having 4 to 12 carbon atom, 30 to 67 weight % long acyl chain having more than 12 carbon atom, an equivalent carbon number 30 to 48 |
| 01/11/2000 | US6013648 Immunomodulators |
| 01/11/2000 | US6013637 Anti-acne method and composition |
| 01/11/2000 | US6013626 To inhibit the proliferation of mammalian cells; antitumor agents |
| 01/11/2000 | US6013619 Applying gas positive end-expiratory pressure with ventilator into lung section of mammal, instilling lavage composition containing dilute surfactant in a pharmaceutically acceptable aqueous medium into lung, removing pulmonary fluid |
| 01/11/2000 | US6013521 Culture system used for the maintenance of neuronal tissues; for use in the treatment of neuronal disorders and detection of neuronal modulators |
| 01/11/2000 | US6013497 Polynucleotide sequence that codes a polypeptide; bactericides |
| 01/11/2000 | US6013479 Human Emr1-like G protein coupled receptor |
| 01/11/2000 | US6013476 DNA encoding tumor necrosis related receptor TR7 |
| 01/11/2000 | US6013455 Polynucleotides which identify and encode protein kinase homologs, amino acid sequences encoding pkh; methods of pkh production with expression vectors; hybridizes under given conditions |
| 01/11/2000 | US6013454 Kinesin-like motor protein |
| 01/11/2000 | US6013450 CAF1-related protein |
| 01/11/2000 | US6013281 Method of making a pharmaceutical dosage form comprising a proton pump inhibitor |
| 01/11/2000 | US6013278 Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
| 01/11/2000 | US6013257 Neurotactin and uses therefor |
| 01/06/2000 | WO2000000825A2 Detection and modulation of cellular immunity to immune privileged antigens |
| 01/06/2000 | WO2000000634A2 METHODS OF INHIBITING $i(HELICOBACTER PYLORI) |
| 01/06/2000 | WO2000000622A2 Human oxidoreductase proteins |
| 01/06/2000 | WO2000000610A2 Human signal peptide-containing proteins |
| 01/06/2000 | WO2000000609A2 Molecules associated with apoptosis |
| 01/06/2000 | WO2000000604A1 Methods and compositions for modulating spermatogenesis |
| 01/06/2000 | WO2000000599A2 Composition for the induction of apoptosis in target cells |
| 01/06/2000 | WO2000000587A1 Methods of expanding and selecting disease associated t-cells |
| 01/06/2000 | WO2000000510A2 Growth factor modulators |
| 01/06/2000 | WO2000000207A1 Treatment of hyperproliferative disorders |
| 01/06/2000 | WO2000000202A1 Method for inhibiting c-jun expression using jak-3 inhibitors |
| 01/06/2000 | WO2000000195A1 Pharmaceutical composition for the treatment of diabetes |
| 01/06/2000 | WO2000000186A1 Method of treating topical ailments |
| 01/06/2000 | WO2000000182A2 Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies |
| 01/06/2000 | WO2000000161A2 Methods for identification of tef-3 interacting factors |
| 01/06/2000 | WO2000000120A1 Methods and transdermal compositions for pain relief |
| 01/06/2000 | WO1999058505A3 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
| 01/06/2000 | WO1999057270A3 Human receptor molecules |
| 01/06/2000 | WO1999055900A3 Gcp |
| 01/06/2000 | WO1999055855A3 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth |
| 01/06/2000 | WO1999051185A3 Human galactosyl transferases |
| 01/06/2000 | WO1999000137A3 Induction of an activated myeloid dendritic cell phenotype |
| 01/06/2000 | CA2337999A1 Method for inhibiting c-jun expression using jak-3 inhibitors |
| 01/06/2000 | CA2336382A1 Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens |
| 01/06/2000 | CA2335837A1 Methods and transdermal compositions for pain relief |
| 01/06/2000 | CA2335516A1 Methods of expanding and selecting disease associated t-cells |
| 01/06/2000 | CA2332379A1 Molecules associated with apoptosis |
| 01/06/2000 | CA2332121A1 Methods for inhibiting tef-3 activity |
| 01/06/2000 | CA2331779A1 Methods and compositions for modulating spermatogenesis |
| 01/06/2000 | CA2331386A1 Human signal peptide-containing proteins |
| 01/06/2000 | CA2331380A1 Human oxidoreductase proteins |
| 01/06/2000 | CA2330565A1 Growth factor modulators |
| 01/05/2000 | EP0969091A2 Leptin receptor gene-related protein |
| 01/05/2000 | EP0968720A2 Gastric emptying-promoting composition |
| 01/05/2000 | EP0968432A1 Growth factor-dependent diseases |
| 01/05/2000 | EP0968304A1 Identification of inhibitors of protein tyrosine kinase 2 |